To The Moon

Sign Up

ARKG Investment Tracker

Source from：official website ARKG is an exchange-traded fund (ETF) managed by Cathie Wood, focusing on stocks related to the genomic revolution. The "ARK Genomic Revolution Fund Guru Tracker" is based on ARKG's daily disclosure reports, helping investors track its investment strategy.

    • ARKG Investment TrackerARKG Investment Tracker
      ·05-21
      ARKG Investment Tracker position change: Decreased position in Veracyte by 5,800 shares, the number of shares held decreased 0.65% compared to the previous period and now represents 3.54% of the total position.
      269Comment
      Report
    • ARKG Investment TrackerARKG Investment Tracker
      ·05-21
      ARKG Investment Tracker position change: Decreased position in Natera by 1,585 shares, the number of shares held decreased 0.64% compared to the previous period and now represents 4.5% of the total position.
      223Comment
      Report
    • ARKG Investment TrackerARKG Investment Tracker
      ·05-21
      ARKG Investment Tracker position change: Decreased position in GeneDx Holdings by 2,765 shares, the number of shares held decreased 0.64% compared to the previous period and now represents 1.74% of the total position.
      201Comment
      Report
    • ARKG Investment TrackerARKG Investment Tracker
      ·05-21
      ARKG Investment Tracker position change: Decreased position in Tempus AI by 13,140 shares, the number of shares held decreased 0.65% compared to the previous period and now represents 8.43% of the total position.
      283Comment
      Report
    • ARKG Investment TrackerARKG Investment Tracker
      ·05-21
      ARKG Investment Tracker position change: Decreased position in Recursion Pharmaceuticals, Inc. by 75,870 shares, the number of shares held decreased 0.65% compared to the previous period and now represents 3.22% of the total position.
      516Comment
      Report
    • ARKG Investment TrackerARKG Investment Tracker
      ·05-21
      ARKG Investment Tracker position change: Decreased position in Prime Medicine, Inc. by 29,780 shares, the number of shares held decreased 0.65% compared to the previous period and now represents 1.23% of the total position.
      198Comment
      Report
    • ARKG Investment TrackerARKG Investment Tracker
      ·05-21
      ARKG Investment Tracker position change: Decreased position in Schrodinger Inc. by 12,655 shares, the number of shares held decreased 0.65% compared to the previous period and now represents 2.24% of the total position.
      157Comment
      Report
    • ARKG Investment TrackerARKG Investment Tracker
      ·05-21
      ARKG Investment Tracker position change: Decreased position in Pacific Biosciences of California by 132,580 shares, the number of shares held decreased 1.29% compared to the previous period and now represents 1.11% of the total position.
      842Comment
      Report
    • ARKG Investment TrackerARKG Investment Tracker
      ·05-21
      ARKG Investment Tracker position change: Decreased position in Eli Lilly by 75 shares, the number of shares held decreased 0.64% compared to the previous period and now represents 1.11% of the total position.
      230Comment
      Report
    • ARKG Investment TrackerARKG Investment Tracker
      ·05-21
      ARKG Investment Tracker position change: Decreased position in Intellia Therapeutics by 42,300 shares, the number of shares held decreased 1.29% compared to the previous period and now represents 3.92% of the total position.
      236Comment
      Report
       
       
       
       

      Most Discussed